

PUBLICATIONS

1. Ko D, Pande A, Lin KJ, Cervone A, **Bessette LG**, Lee SB, Cheng S, Glynn RJ, Kim DH. "Utilization of P2Y12 Inhibitors in Older Adults with ST-Elevation Myocardial Infarction and Frailty" *AJC: American Journal of Cardiology*. *In press*.
2. Yoshida K, Cai T, **Bessette LG**, Kim E, Lee SB, Zabolka LE, Sun A, Mastrorilli JM, Oduol TA, Liu J, Solomon DH, Kim SC, Desai RJ, Liao KP. "Improving the accuracy of automated gout flare ascertainment using natural language processing of electronic health records and linked Medicare claims data." *Pharmacoepidemiol Drug Saf*. *In Press*.
3. Shin H, Wang SV, Kim DH, Alt E, Mahesri M, **Bessette LG**, Schneeweiss S, Najafzadeh M. "Predicting treatment effects of a new-to-market drug in clinical practice based on phase III randomized trial results" *CPT*. *In press*.
4. Kar S*, **Bessette LG***, Wyss R, Kesselheim AS, Lin KJ. "The Impact of Electronic Health Record Discontinuity on Prediction Modeling" *PLOS ONE*. *In press*.
5. Sison SDM, Lin KJ, Najafzadeh M, Ko D, Paterno E, **Bessette LG**, Zakoul H, Kim DH. "Common Non-Cardiovascular Multimorbidity Groupings and Clinical Outcomes in Older Adults with Major Cardiovascular Disease" *JAGS*. *In press*.
6. Suissa K, WyssR, Lu Z, **Bessette LG**, York C, Tsacogianis TN, Lin KJ. "Development and Validation of a Claims-Based Model to Predict Levels of Obesity" *AJE*. *In press*.
7. Wang SV, Schneeweiss S; RCT-DUPLICATE Initiative; Franklin JM, Desai RJ, Feldman W, Garry EM, Glynn RJ, Lin KJ, Paik J, Paterno E, Suissa S, D'Andrea E, Jawaid D, Lee H, Pawar A, Sreedhara SK, Tesfaye H, **Bessette LG**, Zabolka L, Lee SB, Gautam N, York C, Zakoul H, Concato J, Martin D, Paraoan D, Quinto K. "Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses: Results of 32 Clinical Trials" *JAMA*. 2023 Apr 25;329(16):1376-1385. doi: 10.1001/jama.2023.4221.
8. Lin KJ, Singer DE, Bykov K, **Bessette LG**, Mastrorilli JM, Cervone A, Kim DH. "Dementia and comparative effectiveness and safety of oral anticoagulants." *JAMA Netw Open*. 2023 Mar 1;6(3):e234086. doi: 10.1001/jamanetworkopen.2023.4086.
9. Simon TG, Schneeweiss S, Wyss R, Lu Z, **Bessette LG**, York C, Lin KJ. "Development and Validation of a Novel Tool to Predict Model for End-Stage Liver Disease (MELD) Scores in Cirrhosis, Using Administrative Datasets". *Clin Epidemiol*. 2023 Mar 14;15:349-362. doi: 10.2147/CLEP.S387253.
10. Mansour O, Paik JM, Wyss R, Mastrorilli JM, **Bessette LG**, Lu Z, Tsacogianis T, Lin KJ. "A Novel chronic kidney disease phenotyping algorithm using combined electronic health record and claims data." *Clin Epidemiol*. 2023 March 8. doi: 10.2147/CLEP.S397020.
11. Zhang Y, Wilkins JM, **Bessette LG**, York C, Vincent Wong V, Lin KJ. "Antipsychotic medication use among older adults following infection-related hospitalization among older adults." *JAMA Netw Open*. 2023 Feb 1;6(2):e230063. doi: 10.1001/jamanetworkopen.2023.0063.
12. Wyss R, Plasek JM, Zhou L, **Bessette LG**, Schneeweiss S, Rassen JA, Tsacogianis T, Lin KJ. "Scalable feature engineering from electronic free text notes to supplement confounding adjustment of claims-based pharmacoepidemiologic studies." *Clin Pharmacol Ther*. 2022 Dec 17. doi: 10.1002/cpt.2826. Epub ahead of print. PMID: 36528788.
13. Ko D, Lin KJ, **Bessette LG**, Lee SB, Walkey, AJ, Cheng S, Kim E, Glynn RJ, Kim DH. "Trends in Use of Oral Anticoagulants in Older Adults With Newly Diagnosed Atrial Fibrillation, 2010-2020." *JAMA Netw Open*. 2022;5(11):e2242964. doi:10.1001/jamanetworkopen.2022.42964.
14. Desai RJ, Glynn RJ, Everett BM, Schneeweiss S, Wexler DJ, **Bessette LG**, Déruaz-Luyet A, Vedin O, Brodovicz K, Paterno E. "Comparative effectiveness of Empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care". *Am Heart J*. 2022 Sep 21;254:203-215. doi: 10.1016/j.ahj.2022.09.008.

15. Wang SV, Sreedhara SK, **Bessette LG**, Schneeweiss S. “Understanding variation in the results of real-world evidence studies that seem to address the same question”. *J Clin Epidemiol*. 2022 Sep 6;151:161-170. doi: 10.1016/j.jclinepi.2022.08.012.
16. Wang SV, Sreedhara SK, Schneeweiss S, Franklin J, Gagne J, Huybrechts K, Patorno E, Jin Y, Lee M, Mahesri M, Pawar A, Barberio J, **Bessette LG**, Chin K, Gautam N, Ortiz A, Sears E, Stefanini K, Zakarian M, Dejene S, Rogers J, Brill D, Landon J, Lii J, Tsacogianis T, Vine S, Garry E, Gibbs L, Gierada M, Isaman D, Payne E, Alwardt S, Bartels D, Bate A, Bourke A, Brown J, Chan A, Choi NK, Filion K, Hallas J, Happe L, Hennessy S, Jonsson P, Kahler K, Makady A, Martin D, Nguyen M, Nosek B, Sørensen H, Seeger J, Tugwell P, Shrank W, Willke R, Smeeth L, Winkelmayer W. “Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions”. *Nat Commun*. 2022 Aug 31;13(1):5126. doi: 10.1038/s41467-022-32310-3.
17. Paik JM, Patorno E, Zhuo M, **Bessette LG**, York C, Gautam N, Kim DH, Kim SC. “Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data.” *Pharmacoepidemiol Drug Saf*. 2022 Apr;31(4):467-475. doi: 10.1002/pds.5398. Epub 2021 Dec 23. PMID: 34908211; PMCID: PMC8917076.
18. Lauffenburger JC, Yom-Tov E, Keller PA, McDonnell ME, **Bessette LG**, Fontanet CP, Sears ES, Kim E, Hanken K, Buckley JJ, Barlev RA, Haff N, Choudhry NK. “REinforcement learning to Improve Non-adherence For diabetes treatments by Optimizing Response and Customizing Engagement (REINFORCE): study protocol of a pragmatic randomized trial.” *BMJ Open*. In Press.
19. Patorno E, Pawar A, Wexler DJ, Glynn RJ, **Bessette LG**, Paik JM, Najafzadeh M, Brodovicz KG, Déruaz-Luyet A, Schneeweiss S, Bessette LG, Santiago Ortiz A, Kulldorff M, Schneeweiss S. “Effectiveness and safety of empagliflozin in routine care patients: results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.” *Diabetes Obes. Metab*. 2021 Nov. doi: 10.1111/dom.14593. PMID: 34729891.
20. Zhuo M, Hawley CE, Paik JM, **Bessette LG**, Wexler DJ, Kim DH, Tong AY, Kim SC, Patorno E. “Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes.” *JAMA Netw Open*. 2021 Oct 1;4(10):e2130762. doi: 10.1001/jamanetworkopen.2021.30762.
21. Patorno E, Htoo PT, Glynn RJ, Schneeweiss S, Wexler DJ, Pawar A, **Bessette LG**, Chin K, Everett BM*, Kim SC*. “Sodium-glucose cotransporter-2 inhibitors. vs. glucagon-like peptide 1 receptor agonists and the risk of cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease”. *Ann Intern Med*. Accepted on 17 August 2021.
22. Pawar A, Desai RJ, He M, **Bessette L**, Kim SC. “Comparative Risk of Non-vertebral Fractures Among Rheumatoid Arthritis Patients Treated with Biologic or Targeted-Synthetic DMARDs”. *ACR Open Rheumatol*. 2021 Jul 1. doi: 10.1002/acr2.11292.
23. Kim DH, Pawar A, Gagne JJ, **Bessette LG**, Lee H, Glynn RJ, Schneeweiss S. “Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation”. *Ann Intern Med*. 2021 July 20. doi.org/10.7326/M20-7141.
24. Lee H, He M, Cho SK, **Bessette LG**, Tong AY, Merola JF, Wegrzyn LR, Kilpatrick RD, Kim SC. “Validation of Claims-Based Algorithms to Identify Patients with Psoriasis”. *Pharmacoepidemiol Drug Saf*. 2021 Mar 13. doi: 10.1002/pds.5229.
25. Atayde A, Hauc SC, **Bessette LG**, Danckers H, Saitz R. “Changing the narrative: a call to end stigmatizing terminology related to substance use disorders.” *Addiction Research & Theory*. 2021 Jan 25. doi: 10.1080/16066359.2021.1875215
26. Patorno E, Pawar A, **Bessette LG**, Kim DH, Dave C, Glynn RJ, Munshi MN, Schneeweiss S, Wexler D, Kim SC. “Comparative effectiveness and safety of SGLT2 inhibitors vs. GLP-1 receptor agonists in older adults”. *Diabetes Care*. 2021 Jan 25. doi: 10.2337/dc20-1464.

27. Wang SV, Pinheiro S, Hua W, Arlett P, Uyama Y, Berlin JA, Bartels DB, Kahler K, **Bessette LG**, Schneeweiss S. "STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies." *BMJ*. 2021 Jan 12. <https://doi.org/10.1136/bmj.m4856>.
28. Franklin JM, Paterno E, Desai RJ, Glynn RJ, Martin D, Quinto K, Pawar A, **Bessette LG**, Lee H, Garry EM, Gautam N, Schneeweiss S. "Emulating randomized clinical trials with nonrandomized real-world evidence studies: First results from the RCT DUPLICATE initiative." *Circulation*. 2020 Dec 17. doi.org/10.1161/CIRCULATIONAHA.120.051718.
29. Gautam N, **Bessette L**, Pawar A, Levin R, Kim DH. "Updating International Classification of Diseases Ninth Revision to Tenth Revision of a Claims-Based Frailty Index." *J Gerontol A Biol Sci Med Sci*. 2020 Jun 12;glaa150. doi: 10.1093/gerona/glaa150.
30. **Bessette LG**, Hauc SC, Danckers H, Atayde A, Saitz R. "The *Associated Press Stylebook* Changes and the Use of Addiction-related Stigmatizing Terms in News Media." *Substance Abuse*. 2020 Apr 29;1-4. doi: 10.1080/08897077.2020.1748167.
31. Huybrechts KF, Bateman BT, Pawar A, **Bessette LG**, Mogun H, Levin R, Li H, Motsko S, Scantamburlo Fernandes MF, Upadhyaya HP, Hernandez-Diaz S. "Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study." *BMJ*. 2020 Feb 19;368:m237. doi: 10.1136/bmj.m237.
32. Paterno E, Najafzadeh M, Pawar A, Franklin JM, Déruaz-Luyet A, Brodovicz KG, Santiago Ortiz A, **Bessette LG**, Kulldorff M, Schneeweiss S. "The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study program: Study design, validity, and exposure accrual for a real-world evaluation of empagliflozin in routine clinical care." *Endocrinol Diabetes Metab*. 2019 Nov 26;3(1):e00103. doi: 10.1002/edm2.103. eCollection 2020 Jan.
33. Paterno E, Pawar A, Franklin JM, Najafzadeh M, Déruaz-Luyet A, Brodovicz KG, Sambevski S, **Bessette LG**, Santiago Ortiz A, Kulldorff M, Schneeweiss S. "Empagliflozin and the risk of heart failure hospitalization in routine clinical care: a first analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study." *Circulation*. 2019 Jun 18;139(25):2822-2830. doi: 10.1161/CIRCULATIONAHA.118.039177. Epub 2019 Apr 8.

PUBLISHED ABSTRACTS

1. Do K, Lin JK, Najafzadeh M, Cheng S, Kim E, **Bessette LG**, Walkey AJ, Kim DH. "Abstract 10780: Uptake of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation in 2010-2018". *Circulation*. 2021;144:A10780. doi: 10.1161/circ.144.suppl_1.10780.
2. Paterno E, Tesfaye H, Wexler DJ, Glynn R, Najafzadeh M, **Bessette LG**, Zakoul H, Koeneman L, Déruaz-Luyet A, Schneeweiss S. "792-P: Comparative Safety of Empagliflozin in Routine Care Patients: Interim Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study". *Diabetes* 2021;70(Supplement_1):792-P. doi: 10.2337/db21-792-P.
3. Paterno E, Tesfaye H, Wexler DJ, Glynn R, Najafzadeh M, **Bessette LG**, Zabolka L, Koeneman L, Déruaz-Luyet A, Schneeweiss S. "320-OR: Cardiovascular Effectiveness of Empagliflozin in Patients with and without Cardiovascular Disease". *Diabetes* 2021;70(Supplement_1):320-OR. doi: 10.2337/db21-320-OR.
4. Sison SM, **Bessette LG**, Lee SB, Lu Z, Najafzadeh M, Paterno E, Kim DH. "Non-Cardiac Multimorbidity and Clinical Outcomes in Older Adults with Heart Failure". *J Am Geriatr Soc*. 2021 Apr. doi: 10.1111/jgs.17115.
5. Paterno E, Pawar A, **Bessette LG**, Kim DH, Dave C, Glynn RJ, Munshi MN, Schneeweiss S, Wexler DJ. "Comparative effectiveness and safety of SGLT2 inhibitors vs GLP-1 receptor agonists among real-world older adults". *Pharmacoepidemiol Drug Saf*. 2020 Oct;29 Suppl 3:3-649. doi: 10.1002/pds.5114.
6. Paterno E, Pawar A, Franklin JM, Najafzadeh M, Wexler DJ, Déruaz-Luyet A, Brodovicz KG, **Bessette L**, Schneeweiss S. "Cardiovascular effectiveness of empagliflozin compared to DPP4 inhibitors and to GLP1 receptor agonists: Interim analysis from the empagliflozin comparative effectiveness and safety (EMPRISE) study". *Pharmacoepidemiol Drug Saf*. 2020 Oct;29 Suppl 3:3-649. doi: 10.1002/pds.5114.

7. Wang SV, **Bessette L**, Stefani K, Fireman B, Lewis N, Duffy J, McNeill M, Vine S, Huybrechts K, Kulldorff M. "Personal history of febrile seizure increases risk of measles-mumps-rubella vaccine attributable seizure". *Pharmacoepidemiol Drug Saf*. 2020 Oct;29 Suppl 3:3-649. doi: 10.1002/pds.5114.
8. Patorno E, Pawar A, **Bessette L**, Franklin J, Najafzadeh M, Wexler D, Déruaz-Luyet A, Brodovicz KG, Schneeweiss S. "Effectiveness and safety of empagliflozin in routine care patients: interim results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study". *Diabetologia*. 2020 Sep;63(Suppl 1):1-485. doi: 10.1007/s00125-020-05221-5.
9. Patorno E, Pawar A, **Bessette LG**, Franklin JM, Najafzadeh M, Wexler DJ, Déruaz-Luyet A, Brodovicz KG, Schneeweiss S. "134-LB: Effectiveness and Safety of Empagliflozin in Routine Care Patients: Interim Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study". *Diabetes* 2020;69(Supplement_1):134-LB. doi: 10.2337/db20-134-LB.
10. Patorno E, Pawar A, **Bessette LG**, Najafzadeh M, Wexler DJ, Franklin JM, Déruaz-Luyet A, Brodovicz KG, Koeneman L, Schneeweiss S. "133-LB: Cardiovascular Outcomes in Older Adults Initiating Empagliflozin vs. DPP-4 Inhibitors and GLP-1 Receptor Agonists: A Subgroup Analysis from the EMPRISE Study". *Diabetes* 2020;69(Supplement_1):133-LB. doi: 10.2337/db20-133-LB.
11. Najafzadeh M, Pawar A, Déruaz-Luyet A, Brodovicz KG, Ustyugova A, **Bessette LG**, Gautam N, Schneeweiss S, Patorno E. "Reduced healthcare utilization in patients using Empagliflozin: An interim analysis from the Empagliflozin comparative effectiveness and safety (EMPRISE) study". *Pharmacoepidemiol Drug Saf*. 2019 Aug;28 Suppl 2:5-586. doi: 10.1002/pds.4864.
12. Patorno E, Pawar A, Franklin JM, Najafzadeh M, Déruaz-Luyet A, Brodovicz KG, Sambevski S, **Bessette LG**, Kulldorff M, Schneeweiss S. "Empagliflozin selected cardiovascular and safety outcomes in routine care: first results from the empagliflozin comparative effectiveness and safety (EMPRISE) study". *Pharmacoepidemiol Drug Saf*. 2019 Aug;28 Suppl 2:5-586. doi: 10.1002/pds.4864.
13. Schneeweiss S, Pawar A, Franklin JM, Najafzadeh M, Déruaz-Luyet A, Brodovicz K, **Bessette LG**, Kulldorff M, Patorno E. "The risk of heart failure hospitalisation among routine care patients initiating empagliflozin vs glucagon-like peptide-1 receptor agonists: a substudy from EMPRISE". *Diabetologia*. 2019 Sep;62(Suppl 1):1-600. doi: 10.1007/s00125-019-4946-6.
14. Patorno E, Pawar A, Franklin JM, Najafzadeh M, Déruaz-Luyet A, Brodovicz KG, Sambevski S, **Bessette LG**, Kulldorff M, Schneeweiss S. "Empagliflozin selected cardiovascular and safety outcomes in routine care: first results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study". *Diabetologia*. 2019 Sep;62(Suppl 1):1-600. doi: 10.1007/s00125-019-4946-6.
15. Patorno E, Kim DH, Pawar A, Schneeweiss S, Glynn RJ, Munshi M, **Bessette LG**, Kim SC. "156-OR: Risk-Benefit of SGLT2 Inhibitors (SGLT2i) vs. GLP-1 Receptor Agonists (GLP-1RA) in Routine Care of Older Adults". *Diabetes* 2019;68(Supplement_1):156-OR. doi: 10.2337/db19-156-OR.
16. Pawar A, Patorno E, Déruaz-Luyet A, Brodovicz KG, Ustyugova AV, Gautam N, **Bessette LG**, Schneeweiss S, Najafzadeh M. "1193-P: Health-Care Costs and Medication Burden in Routine Care Initiators of Empagliflozin: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study". *Diabetes* 2019;68(Supplement_1):1193-P. doi: 10.2337/db19-1193-P.
17. Patorno E, Pawar A, Franklin JM, Najafzadeh M, Déruaz-Luyet A, Brodovicz KG, Sambevski S, **Bessette LG**, Kulldorff M, Schneeweiss S. "249-OR: Empagliflozin Selected Cardiovascular and Safety Outcomes in Routine Care: First Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study". *Diabetes* 2019;68(Supplement_1):249-OR. doi: 10.2337/db19-249-OR.
18. Patorno E, Pawar A, Schneeweiss S, Glynn RJ, Kim DH, Everett BM, **Bessette LG**, Kim SC. "247-OR: Real-World Effectiveness of SGLT2 Inhibitors vs. GLP-1 Receptor Agonists in Patients With and Without Cardiovascular Disease". *Diabetes* 2019;68(Supplement_1):247-OR. doi: 10.2337/db19-247-OR.
19. Patorno E, Pawar A, Franklin JM, Najafzadeh M, Wexler D, Déruaz-Luyet A, Brodovicz KG, **Bessette L**, Schneeweiss S. "Abstract 11928: Cardiovascular Effectiveness of Empagliflozin Compared to DPP4 Inhibitors and to GLP1 Receptor Agonists: Interim Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study". *Circulation*. 2019;140:A11928.
20. Najafzadeh M, Pawar A, Déruaz-Luyet A, Brodovicz KG, Ustyugova A, **Bessette L**, Gautam N, Schneeweiss S, Patorno E. "Reduced Healthcare Utilization in Patients Using Empagliflozin: An Interim

Analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study”. *JMCP*. 2019;25(3-a) S39.

21. Najafzadeh M, Pawar A, Déruaz-Luyet A, Brodovicz KG, Ustyugova A, **Bessette L**, Gautam N, Schneeweiss S, Patorno E. “Healthcare Costs in Patients Using Empagliflozin: An Interim Analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study”. *JMCP*. 2019;25(3-a) S39.
22. Pawar A, Patorno E, Déruaz-Luyet A, Brodovicz KG, Ustyugova A, **Bessette L**, Santiago Ortiz A, Schneeweiss S, Najafzadeh M. “Comparative Healthcare Costs and Medication Burden in Real-World Patients Augmenting Metformin Monotherapy with Empagliflozin from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study”. *JMCP*. 2019;25(3-a) S39-S40.
23. Patorno E, Pawar A, Franklin JM, Najafzadeh M, Déruaz-Luyet A, Brodovicz KG, **Bessette LG**, Kulldorff M, Schneeweiss S. “Comparative Effectiveness and Safety of Empagliflozin: an interim analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study”. *J Am Coll Cardiol*. 2019 Mar, 73 (9_Supplement_1) 683.

INTERNATIONAL PRESENTATIONS

1. **Presenter and First-Author**, “Development and Validation of an Intracranial Hemorrhage Risk Score in Older Adults with Atrial Fibrillation Treated with Oral Anticoagulant”. Accepted for oral presentation at: American Geriatrics Society 2023; 2023 Annual Scientific Meeting May 4-6.
2. **Presenter and First-Author**, “Physical Activity and Sedentary Time Associations with Non-Fracture Fall Injury (NFFI) and Fracture”. Accepted for late-breaker poster presentation at: Gerontological Society of America Conference 2022; 2022 Nov 2-6.
3. **Co-Author**, "Improving the Accuracy of Automated Gout Flare Ascertainment Using Natural Language Processing of Medical Records and Linked Medicare Claims Data for Real-world Comparative Effectiveness Research". Accepted for oral presentation at: American College of Rheumatology Convergence 2022; 2022 Nov 10-14.
4. **Presenter and Co-Author**, “Predicting Risks of Intracranial Bleeding in Older Adults with Atrial Fibrillation to Aid Prescribing Decisions”. Accepted for lightning session oral presentation at: 38th ICPE; 2022 Aug 24-28.
5. **Presenter and Co-Author**, “The Impact of Electronic Health Record Discontinuity on Prediction Modeling”. Accepted for lightning session oral presentation at: 38th ICPE; 2022 Aug 24-28.
6. **Presenter and Co-Author**, “Utilization of Antipsychotics for Delirium After Hospitalization for COVID-19 and Other Infections”. Accepted for spotlight poster presentation at: 38th ICPE; 2022 Aug 24-28.
7. **Presenter and Co-Author**, “Comparative Effect of Oral Anticoagulants on Home Time Loss and Cost: The Role of Frailty”. Accepted for poster presentation at: 38th ICPE; 2022 Aug 24-28.
8. **Presenter and Co-Author**, “Development and Validation of a Chronic Kidney Disease Phenotype Using Combined Electronic Health Record and Claims Data”. Accepted for poster presentation at: 38th ICPE; 2022 Aug 24-28.
9. **Co-Author**, “Claims-based Model to Predict Obesity in Older Patients”. Accepted for oral presentation at: 38th ICPE; 2022 Aug 24-28.
10. **Co-Author**, “Predicting Treatment Effects of a New Drug in a Target Population Based on Randomized Controlled Trial Results”. Accepted for oral presentation at: 38th ICPE; 2022 Aug 24-28.
11. **Co-Author**, “Improving The Accuracy of Automated Gout Flare Ascertainment Using Natural Language Processing of Medical Records and Linked Medicare Claims Data”. Accepted for poster presentation at: 38th ICPE; 2022 Aug 24-28.
12. **Co-Author**, “Scalable Feature Engineering from Electronic Free Text Notes to Supplement Confounding Adjustment of Claims-Based Pharmacoepidemiologic Studies”. Accepted for poster presentation at: 38th ICPE; 2022 Aug 24-28.

13. **Co-Author**, "Uptake of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation in 2010-2018". American Heart Association's 2021 Scientific Sessions; 2021 Nov 13-15.
14. **Co-Author**, "Comparative safety of empagliflozin in routine care patients: interim results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study." American Diabetes Association 81st Scientific Sessions; 2021 June 25-29; Virtual.
15. **Co-Author**, "Cardiovascular effectiveness of empagliflozin in patients with and without cardiovascular disease." American Diabetes Association 81st Scientific Sessions; 2021 June 25-29; Virtual.
16. **Second-Author**, "Non-Cardiac Multimorbidity and Clinical Outcomes in Older Adults with Heart Failure". Accepted for poster session presentation at: American Geriatrics Society 2021 Virtual Annual Scientific Meeting; 2021 May 13-15; Online.
17. **Co-Author**, "Personal History of Febrile Seizure Increases Risk of Measles-Mumps-Rubella Vaccine Attributable Seizure." Accepted for oral presentation at: International Conference on Pharmacoepidemiology & Therapeutic Risk Management ICPE All Access 35 Years of Real-World Science; 2020 September; Online.
18. **Co-Author**, "Effectiveness and safety of empagliflozin in routine care patients: interim results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study" Accepted for poster session presentation at: European Association for the Study of Diabetes EASD Virtual Meeting; 2020 September; Online.
19. **Co-Author**, "Comparative Effectiveness and Safety of SGLT2 Inhibitors vs. GLP-1 Receptor Agonists Among Real-world Older Adult." Accepted for oral presentation at: International Conference on Pharmacoepidemiology & Therapeutic Risk Management ICPE All Access 35 Years of Real-World Science; 2020 September; Online.
20. **Co-Author**, "Cardiovascular Effectiveness of Empagliflozin Compared to DPP4 Inhibitors and to GLP1 Receptor Agonists: Interim Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study" Accepted for oral presentation at: International Conference on Pharmacoepidemiology & Therapeutic Risk Management ICPE All Access 35 Years of Real-World Science; 2020 September; Online.
21. **Co-Author**, "Effectiveness and Safety of Empagliflozin in Routine Care Patients: Interim Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study". American Diabetes Association 80th Scientific Sessions; 2020 June 12-16; Virtual.
22. **Co-Author**, "133-LB: Cardiovascular Outcomes in Older Adults Initiating Empagliflozin vs. DPP-4 Inhibitors and GLP-1 Receptor Agonists: A Subgroup Analysis from the EMPRISE Study". American Diabetes Association 80th Scientific Sessions; 2020 June 12-16; Virtual.
23. **Co-Author**, "Cardiovascular Effectiveness of Empagliflozin Compared to DPP4 Inhibitors and to GLP1 Receptor Agonists: Interim Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study". American Heart Association's 2019 Scientific Sessions; 2019 Nov 16-18.
24. **Co-Author**, "The risk of heart failure hospitalisation among routine care patients initiating empagliflozin vs glucagon-like peptide-1 receptor agonists: a substudy from EMPRISE". 55th Annual Meeting of European Association for the Study of Diabetes (EASD) Meeting; 2019 September 16-20.
25. **Co-Author**, "Empagliflozin selected cardiovascular and safety outcomes in routine care: first results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study". 55th Annual Meeting of European Association for the Study of Diabetes (EASD) Meeting; 2019 September 16-20.
26. **Co-Author**, "Reduced Healthcare Utilization in Patients Using Empagliflozin: An Interim Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study." Accepted for oral presentation at: International Conference on Pharmacoepidemiology & Therapeutic Risk Management 35th ICPE; 2019 August 24-28; Philadelphia, PA.
27. **Co-Author**, "Empagliflozin Selected Cardiovascular and Safety Outcomes in Routine Care: First Results from Theempagliflozin Comparative Effectiveness and Safety (EMPRISE) Study" Accepted for oral presentation at: International Conference on Pharmacoepidemiology & Therapeutic Risk Management 35th ICPE; 2019 August 24-28; Philadelphia, PA.

28. **Co-Author**, “Empagliflozin Selected Cardiovascular And Safety Outcomes In Routine Care: First Results From the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study.” Accepted for oral presentation at: American Diabetes Association 79th Scientific Sessions; 2019 June 7-11; San Francisco, CA.
29. **Co-Author**, “Healthcare Costs And Medication Burden In Routine Care Initiators Of Empagliflozin: A First Analysis From the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study.” Accepted for poster session presentation at: American Diabetes Association 79th Scientific Sessions; 2019 June 7-11; San Francisco, CA.
30. **Co-Author**, “Real-world Effectiveness Of SGLT2 Inhibitors Vs GLP-1 Receptor Agonists In Patients With And Without Cardiovascular Disease.” Accepted for oral presentation at: American Diabetes Association 79th Scientific Sessions; 2019 June 7-11; San Francisco, CA.
31. **Co-Author**, “Risk-benefit Of SGLT2 Inhibitors (SGLT2i) vs GLP-1 Receptor Agonists (GLP-1 RA) In Routine Care Of Older Adults.” Accepted for oral presentation at: American Diabetes Association 79th Scientific Sessions; 2019 June 7-11; San Francisco, CA.
32. **Co-Author**, “Comparative healthcare costs and medication burden in real-world patients augmenting metformin monotherapy with empagliflozin from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.” Accepted for poster session presentation at: AMCP Managed Care & Specialty Pharmacy Annual Meeting 2019; 2019 March 25-28; San Diego, CA.
33. **Co-Author**, “Reduced healthcare utilization in patients using empagliflozin: an interim analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.” Accepted for poster session presentation at: AMCP Managed Care & Specialty Pharmacy Annual Meeting 2019; 2019 March 25-28; San Diego, CA.
34. **Co-Author**, “Healthcare costs in patients using empagliflozin: an interim analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.” Accepted for poster session presentation at: AMCP Managed Care & Specialty Pharmacy Annual Meeting 2019; 2019 March 25-28; San Diego, CA.
35. **Co-Author**, “Comparative Effectiveness And Safety Of Empagliflozin: an interim analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study.” Accepted for poster session presentation at: American College of Cardiology Scientific Session (ACC.19); 2019 March 16-18; New Orleans, LA.

INTERNAL PRESENTATIONS

1. **Keynote Speaker**, InspirAsian 2023 Celebration, Northeastern University, Asian American Center; Boston, MA.
2. **Presenter and Co-Author**, “Characterization of anti-SIV monoclonal antibody SU24 cloned into a mammalian expression vector.” Poster session presented at: Boston College 2018 Undergraduate Symposium; 2018 May 4; Chestnut Hill, MA.
3. **Presenter and Co-Author**, “Characterization of putative efflux pump genes in *Acinetobacter baumannii*.” Poster session presented at: Boston College 2018 Undergraduate Symposium; 2018 May 4; Chestnut Hill, MA.
4. **Presenter and Co-Author**, “Evolutionary Conservation of the *Neurospora crassa Met16* Gene Through the Complementation of a *Saccharomyces cerevisiae met16* Mutant.” Poster session presented at: Boston College 2017 Undergraduate Research Day; 2017 May 5; Chestnut Hill, MA.